Incyte (INCY) EBITDA Margin (2010 - 2026)

Incyte (INCY) has 17 years of EBITDA Margin data on file, last reported at 41.69% in Q2 2026.

• Quarterly EBITDA Margin fell 194.0% year-over-year to 41.69% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 30.56% (up 476.0% YoY) and the FY2025 annual result came in at 29.46%, up 2802.0% from the prior year.
• EBITDA Margin advanced to 41.69% in Q2 2026, from 23.66% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 43.63% in Q2 2025 to a low of 45.81% in Q2 2024.
• A 5-year average of 17.76% and a median of 19.89% in 2023 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 6611 bps — and 2025, when it surged 8944 bps.
• Tracing INCY's EBITDA Margin over 5 years: stood at 7.56% in 2022, then soared by 144 bps to 18.48% in 2023, then surged by 38 bps to 25.58% in 2024, then declined by 13 bps to 22.29% in 2025, then surged by 87 bps to 41.69% in 2026.
• The last three EBITDA Margin figures came in at 41.69% (Q2 2026), 23.66% (Q1 2026), and 22.29% (Q4 2025), per Business Quant data.